• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.

2017_ABR_Teaser

Download 2017 Valneva Annual Business Report

August 2, 2018  

Valneva Delivers Strong IXIARO® Sales Growth and Reports Further Progress on Key R&D Programs in H1

Read more    

— Stock information

@valnevase




















-
— July 2, 2018
Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate

Read more 
— Financial Calendar

August 2, 2018
Valneva published its H1 2018 financial results.

Press release
H1 financial report
Webcast


See all dates






JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Company Video

– Upcoming conferences


September 7
Goldman Sachs Biotech Symposium, London

October 8-9
European Large & Midcap Event, Paris

October 29-31

World Vaccine Congress Europe, Lisbon

November 13-14
Stifel 2018 Healthcare Conference, New York

Please update your browser...